更新后的功能性移植肾细胞癌全国性研究：它们是不同的实体吗？

Updated National Study of Functional Graft Renal Cell Carcinomas: Are They a Different Entity?

作者信息

Szabla Nicolas, Matillon Xavier, Calves Jehanne, Branchereau Julien, Champy Cécile, Neuzillet Yann, Bessede Thomas, Bouhié Sébastien, Boutin Jean-Marie, Caillet Kevin, Cognard Noelle, Culty Thibaut, De Fortescu Guillaume, Drouin Sarah, Bentellis Imad, Hubert Jacques, Boissier Romain, Sallusto Federico, Sénéchal Cédric, Terrier Nicolas, Thuret Rodolphe, Verhoest Gregory, Waeckel Thibaut, Tillou Xavier

机构信息

CHU de Caen, Urology and Transplantation, Caen Calvados, France.

Hôpital Edouard Herriot, Urology and Transplantation, Lyon, Rhone, France.

出版信息

Urology. 2023 Jan;171:152-157. doi: 10.1016/j.urology.2022.09.020. Epub 2022 Oct 12.

DOI:10.1016/j.urology.2022.09.020

PMID:36243142

Abstract

OBJECTIVE

To analyze de novo graft carcinoma characteristics from our updated national multicentric retrospective cohort.

METHODS

Thirty-two transplant centers have retrospectively completed the database. This database concerns all kidney graft tumors including urothelial, and others type but excludes renal lymphomas over 31 years.

RESULTS

One hundred and fifty twokidney graft carcinomas were diagnosed in functional grafts. Among them 130 tumors were Renal Cell Carcinomas. The calculated incidence was 0.18%. Median age of the allograft at diagnosis was 45.4 years old. The median time between transplantation and diagnosis was 147.1 months. 60 tumors were papillary carcinomas and 64 were clear cell carcinomas. Median tumor size was 25 mm. 18, 64, 21 and 1 tumors were respectively Fuhrman grade 1, 2, 3 and 4. Nephron sparing surgery (NSS) was performed on 68 (52.3%) recipients. Ablative therapy was performed in 23 cases (17.7%). Specific survival rate was 96.8%.

CONCLUSION

This study confirmed that renal graft carcinomas are a different entity: with a younger age of diagnosis; a lower stage at diagnosis; a higher incidence of papillary subtypes.

摘要

目的

通过更新后的全国多中心回顾性队列分析新发移植癌的特征。

方法

32个移植中心回顾性地完成了数据库。该数据库涵盖了所有肾移植肿瘤，包括尿路上皮肿瘤及其他类型，但不包括31年间的肾淋巴瘤。

结果

在功能正常的移植肾中诊断出152例肾移植癌。其中130例肿瘤为肾细胞癌。计算得出的发病率为0.18%。诊断时移植肾的中位年龄为45.4岁。移植与诊断之间的中位时间为147.1个月。60例肿瘤为乳头状癌，64例为透明细胞癌。肿瘤中位大小为25毫米。分别有18例、64例、21例和1例肿瘤为福尔曼1级、2级、3级和4级。68例（52.3%）受者接受了保留肾单位手术（NSS）。23例（17.7%）接受了消融治疗。特异性生存率为96.8%。

结论